




PIPELINE

Candidate: Lasofoxifene – Oral SERM

	Preclinical	Phase 1	Phase 2	Phase 3		
<ul style="list-style-type: none"> • Monotherapy •• Combination Therapy 						
▶ Breast Cancer						
•	ELAINE 1: Lasofoxifene vs. Fulvestrant 				<input type="checkbox"/> <input checked="" type="checkbox"/>	
••	ELAINE 2: Laso + Abemaciclib 				<input type="checkbox"/> <input checked="" type="checkbox"/>	<i>Lilly</i>
••	ELAINE 3: (Registrational) Laso + Abema vs. Abema 				<input checked="" type="checkbox"/> <input type="checkbox"/>	<i>Lilly</i>
••	Laso + mTOR Inhibitor				<input checked="" type="checkbox"/> <input type="checkbox"/>	tbcrc
••	Laso + SARM				<input checked="" type="checkbox"/> <input type="checkbox"/>	

In Planning
Enrollment Complete


▶ Treatment Resistant Tumors (non-ESR1^{mut}) and ESR1^{mut}

- Laso vs. Fulv
- Laso + Palbo vs. Fulv + Palbo

▶ Gynecological Cancer

- /•• Lasofoxifene – Endometrial Cancer

▶ ESR1 Assay



THE UNIVERSITY OF
CHICAGO

UNIVERSITY OF UTAH
HUNTSMAN
CANCER INSTITUTE